Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administ

DOI: 10.1016/j.ajoc.2020.100687
American Journal of Ophthalmology Case Reports, 2020, 18, 100687.

#	Paper	IF	Citations
59	Pharmacological agents in development for diabetic macular edema. *International Journal of Retina and Vitreous*, **2020**, 6, 29	2.9	3
58	Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study. *American Journal of Ophthalmology Case Reports*, **2020**, 20, 100989	1.3	13
57	Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. *Ophthalmology*, **2021**, 128, 1050-1059	7.3	55
56	Brolucizumab. *Reactions Weekly*, **2020**, 1813, 63-63	0	
55	Brolucizumab: the road ahead. *British Journal of Ophthalmology*, **2020**, 104, 1631-1632	5.5	3
54	Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. *Journal of Vitreoretinal Diseases*, **2020**, 4, 269-279	0.7	48
53	Brolucizumab-early real-world experience: BREW study. *Eye*, **2021**, 35, 1045-1047	4.4	18
52	Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment. *Ophthalmology Retina*, **2021**, 5, 519-527	3.8	35
51	Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world. *Eye*, **2021**, 35, 1292-1294	4.4	11
50	Dual-acting therapeutic proteins for intraocular use. *Drug Discovery Today*, **2021**, 26, 44-55	8.8	1
49	[Ophthalmic safety profile of antiangiogenic therapy]. **2021**, 137, 114-122		0
48	Brolucizumab-foreseeable workflow in the current scenario. *Eye*, **2021**, 35, 1548-1550	4.4	6
47	[Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab]. *Ophthalmologe*, **2021**, 1	1.6	1
46	[Bilateral occlusive vasculitis after intravitreal injection of brolucizumab in neovascular age-related macular degeneration]. *Ophthalmologe*, **2021**, 1	1.6	0
45	Three Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic. *Japanese Journal of Ophthalmology*, **2021**, 65, 208-214	2.6	9
44	Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy. *Japanese Journal of Ophthalmology*, **2021**, 65, 199-207	2.6	12
43	[Intraocular inflammation with brolucizumab use : Patient management-diagnosis-therapy]. *Ophthalmologe*, **2021**, 118, 248-256	1.6	5

42	Drug-related adverse effects of antivascular endothelial growth factor agents. *Current Opinion in Ophthalmology*, **2021**, 32, 191-197	5.1	5
41	Inflammatory Complications of Intravitreal Anti-VEGF Injections. *Journal of Clinical Medicine*, **2021**, 10,	5.1	14
40	Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. *British Journal of Ophthalmology*, **2021**,	5.5	18
39	Differing Risks of Occlusive Retinal Vasculitis with Concurrent Intraocular Inflammation Among Intravitreal Antivascular Endothelial Growth Factor Therapies. *Retina*, **2021**, 41, 669-670	3.6	0
38	Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD. *Expert Opinion on Biological Therapy*, **2021**, 21, 553-561	5.4	5
37	Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER. *Ophthalmology Retina*, **2021**,	3.8	5
36	The role of future treatments in the management of neovascular age-related macular degeneration in Europe. *European Journal of Ophthalmology*, **2021**, 31, 2179-2188	1.9	
35	Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. *International Journal of Retina and Vitreous*, **2021**, 7, 37	2.9	8
34	Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam's Razor?. *Ocular Immunology and Inflammation*, **2021**, 1-3	2.8	4
33	Idiopathic retinal arterial occlusive vasculitis in the setting of multiple arterial occlusions. *American Journal of Ophthalmology Case Reports*, **2021**, 22, 101086	1.3	2
32	Biomarkers in Early Response to Brolucizumab on Pigment Epithelium Detachment Associated with Exudative Age-Related Macular Degeneration. *Biomedicines*, **2021**, 9,	4.8	4
31	Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab. *Translational Vision Science and Technology*, **2021**, 10, 21	3.3	1
30	Pharmacologically induced uveitis. *Survey of Ophthalmology*, **2021**, 66, 781-801	6.1	4
29	Is This a 737 Max Moment for Brolucizumab?. *American Journal of Ophthalmology*, **2020**, 216, A7-A8	4.9	6
28	New Age-related Macular Degeneration Injectables. *European Ophthalmic Review*, **2020**, 14, 17	0.6	
27	Side Effects of Brolucizumab. *Journal of Ophthalmic and Vision Research*, **2021**, 16, 670-675	1.2	0
26	Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map. *JAMA Ophthalmology*, **2021**,	3.9	5
25	Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center. *European Journal of Ophthalmology*, **2021**, 11206721211059332	1.9	1

24	An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma.. *Eye*, **2022**,	4.4	2
23	Modern concept of a new group of retinal vasculitis. *Rossiiskii Oftalsmologicheskii Zhurnal*, **2022**, 14, 149-153	0.5	
22	Disease Progression Pathways of Wet AMD: Opportunities for New Target Discovery.. *Expert Opinion on Therapeutic Targets*, **2022**,	6.4	0
21	Literature review and proposal of best practice for ophthalmologists: monitoring of patients following intravitreal brolucizumab therapy.. *Irish Journal of Medical Science*, **2022**, 1	1.9	0
20	Intraocular inflammation secondary to intravitreal brolucizumab treated successfully with Sub-Tenon triamcinolone: A case report.. *American Journal of Ophthalmology Case Reports*, **2022**, 25, 101289	1.3	1
19	Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. *PLoS ONE*, **2021**, 16, e0259879	3.7	5
18	Anti-drug antibodies to brolucizumab and ranibizumab in serum and vitreous of patients with ocular disease.. *Acta Ophthalmologica*, **2022**,	3.7	0
17	Sub-Tenon's capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation.. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2022**, 1	3.8	0
16	Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting.. *Journal of Ophthalmology*, **2022**, 2022, 2659714	2	1
15	Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD.. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2021**,	3.8	0
14	Guía de recomendaciones para el manejo de brolucizumab. *Archivos De La Sociedad Espanola De Oftalmologia*, **2022**,	0.5	
13	First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration. *Frontiers in Pharmacology*, **2022**, 13,	5.6	2
12	Retinal Vasculitis Following Intravitreal Brolucizumab Injection: The First Report in South Korea. *Journal of Retina*, **2022**, 7, 59-64	0.2	0
11	Nuevas Opciones de Anti-VEGF Aprobados por la FDA para el Manejo de la Degeneración Macular Húmeda Asociada a la Edad. *Highlights of Vitreoretina*, **2022**, 15, 21-26	0	
10	Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report. *BMC Ophthalmology*, **2022**, 22,	2.3	0
9	Review of Intraocular Inflammation After Antivascular Endothelial Growth Factor Agents. *International Ophthalmology Clinics*, **2022**, 62, 35-47	1.7	0
8	Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?. *Expert Opinion on Biological Therapy*, 1-17	5.4	0
7	A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. **2022**, 42, 1629-1637		1

6	Age-related macular degeneration and its treatment options. **2022**, 333-342	0
5	Bioengineering of Antibody Fragments: Challenges and Opportunities. **2023**, 10, 122	0
4	Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration. Volume 17, 657-665	0
3	Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data. **2023**, 12, 168-183	0
2	Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration.	0
1	Cytokine profiles in the aqueous humor following brolucizumab administration for exudative age-related macular degeneration.	0